🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Summit says PD-1xVEGF bispecific ivonsecimab misses overall survival in closely-watched lung cancer study $SMMT endpts.com/summit-says-bi…

Lackluster results for Sanofi and Regeneron's IL-33 antibody throw the future of the pipeline drug into question: endpts.com/sanofi-regener…

Astellas licenses Evopoint's Claudin18.2-targeted antibody-drug conjugate for $130m and becomes the latest large pharmaceutical company to ink a deal with a Chinese biotech. endpts.com/astellas-licen…

Moderna's new Covid vaccine has been approved — but in a narrower population than the company studied in its phase 3 — reflecting the new limit's RFK's HHS is putting on the shots: endpts.com/fda-approves-m…

ASCO Monday is the new JPM Sunday: $BMY $BNTX $SAN $BPMC

In one of the largest deals of the year so far, Sanofi will be acquiring Blueprint Medicines for $9.1 billion. endpts.com/sanofi-to-snap…

Bristol Myers will be working with BioNTech on a PD-L1xVEGF asset that the German drugmaker bought from China about six months ago. endpts.com/bristol-myers-…

Lilly's top oncology execs: If a cancer program needs a mid-stage trial, its too mid for Lilly. My look at Lilly's cancer pipeline revamp and its unconventional strategy: endpoints.news/phase-3-or-bus…

#ASCO25: Lilly won't run mid-stage cancer trials. Why? If it doesn't work in Phase 1 "it’s not a drug in our eyes", says Jake Van Naarden. endpts.com/phase-3-or-bus…

Q&A: Sandoz CEO on the natural tension of generics vs. pharma, the coming generic GLP-1 experiment, Trump's tariffs, & more: endpoints.news/qa-sandoz-ceo-…

#ASCO25: Promising advances in cell therapies to treat aggressive brain cancer. The trials are small, but the data revealed last weekend is encouraging where other treatments have shown little effect. endpoints.news/asco25-brain-c…

Q&A: Richard Saynor started out as a pharmacist, then he climbed the ranks of the pharma industry to find himself at the helm of Sandoz. endpoints.news/qa-sandoz-ceo-…

What's happened to the FDA workers DOGE fired? Their last day was meant to be June 2, but many are still getting paid and face an uncertain future. endpoints.news/laid-off-fda-w…

Join us June 10 for our fourth annual virtual event celebrating LGBTQ+ leaders driving change in biopharma. Hear their stories, insights, and perspectives on shaping a more inclusive industry. Register today. events.endpts.com/lgbtq25/regist…

Lilly is making a big play on long-acting incretins, signing a deal worth up to $870M with Sweden’s Camurus for its slow-release drug delivery tech. Camurus shares rose 31%. endpoints.news/eli-lilly-inks…

Fifteen days after a trial failure and GSK’s exit, iTeos is shutting down — a familiar biotech story in 2025. Some argue the turbulence is a sign of a paradoxically healthy ecosystem. endpoints.news/struggling-bio…

AnaptysBio’s PD-1 drug rosnilimab hit its primary endpoint in a Phase 2b rheumatoid arthritis study, showing “JAK-like” efficacy at 28 weeks. Now, the biotech is looking for a partner to take it into phase 3. endpoints.news/anaptysbio-des…

Exclusive: After deep staff cuts, Casma is back with early data on its first autophagy-targeting drug. The biotech plans to enter the clinic in 2026 for Gaucher’s and Parkinson’s. endpoints.news/after-layoffs-…